SCHEMBL4368939

SCHEMBL4368939

N[N+]12C=CN=CC1=C(c1ccc3cn[nH]c3c1)N=C2c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 1/20 0.43
FGFR1 P11362 8/20 0.42
FGFR2 P21802 4/20 0.38
FGFR3 P22607 2/20 0.38
KDR P35968 1/20 0.35
BTK Q06187 1/20 0.34
CHEK2 O96017 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
XDH P47989 1/20 0.32
DYRK3 O43781 1/20 0.32
CLK1 P49759 1/20 0.32
CLK2 P49760 1/20 0.32
CLK3 P49761 1/20 0.32
GSK3B P49841 1/20 0.32
CDK5 Q00535 1/20 0.32
DYRK1A Q13627 1/20 0.32
CDK5R1 Q15078 1/20 0.32
DYRK2 Q92630 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358894 0.85 TNK2 (0.42) TNK2BTKCHEK2XDHPRMT5
SCHEMBL1131147 0.82 NPC1 (0.34) TNK2BTKCHEK2XDHNPC1
SCHEMBL4361491 0.82 BTK (0.38) TNK2BTKCHEK2XDHPRMT5
SCHEMBL4368285 0.80 MAOB (0.40) TNK2BTKCHEK2XDHNPC1
SCHEMBL4352081 0.79 MAOA (0.43) TNK2BTKCHEK2XDHNPC1
SCHEMBL4366293 0.79 TNK2 (0.38) TNK2CHEK2XDHLTA4H
SCHEMBL4360821 0.79 TNK2 (0.38) TNK2FGFR1DYRK1ACLK4NPC1
SCHEMBL4364188 0.78 TNK2 (0.41) TNK2CHEK2
SCHEMBL4353437 0.78 MAPK14 (0.36) TNK2BTKXDHNPC1LTA4H
SCHEMBL4357979 0.78 LTA4H (0.42) TNK2BTKNPC1LTA4HRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US claimed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 TNK2 2837/4885FGFR1 163/4885FGFR2 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.